Senior Scientist / Director, Genomics Princess Margaret Cancer Centre / Ontario Institute for Cancer Research Toronto, Ontario, Canada
Description: Cell-free DNA (cfDNA) testing is rapidly transforming cancer care by offering a non-invasive, highly sensitive method for detecting genetic alterations, monitoring tumor evolution, and guiding treatment decisions. This presentation will explore the latest innovations in cfDNA analysis, focusing on blood-based liquid biopsies. Attendees will gain insights into how cfDNA testing supports personalized medicine by enabling early detection, real-time monitoring of treatment response, and identification of resistance mutations. We will also address current adoption challenges, clinical integration strategies, and future directions of this powerful diagnostic tool—highlighting its growing impact on improving patient outcomes and advancing precision oncology.
Learning Objectives: - Explain the role of cell-free DNA testing in cancer diagnostics and treatment monitoring. - Differentiate between blood-based and non-blood-based cfDNA applications and their clinical relevance. - Identify key advancements in cfDNA technology and their impact on personalized cancer care.
